Please assess the completion status of the following clinical trial:

Trial Title: FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC~* No prior therapy for IDC or ILC~* Clinical need for local disease staging with breast MR (Group A only)~* Clinical need for neoadjuvant chemotherapy (Group B only)~* Patients must provide written informed consent~Exclusion Criteria:~* Age \<21 years~* Men~* Pregnancy or lactation~* Patients who have already started treatment for the current malignancy~* Patients who cannot undergo PET scanning (i.e. because of weight limits)~* Patients who are known to have contraindication for MRI (e.g. metal implants)~* Patients may only participate in group #1 or group #2, but not both

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Local staging patients (Type: EXPERIMENTAL): Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
- Neoadjuvant chemotherapy patients (Type: EXPERIMENTAL): Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.

Based on this trial design, predict the completion outcome and termination type (if applicable).